###### Strengths and limitations of this study

-   This is the first multinational study investigating the association of the National Early Warning Score (NEWS) and adverse outcomes at emergency department admission.

-   This is the first study evaluating additional impact of inflammatory biomarkers on NEWS.

-   Due to its design as a secondary analysis of an observational study, results are at best hypothesis generating.

-   There is the possibility of a selection bias due to exclusion of patients with missing vital status data.

Introduction {#s1}
============

With increasingly overwhelmed emergency departments (EDs), it is vital that well-validated risk stratification systems are implemented to rapidly identify and efficiently respond to patients at risk since delays in treatment may result in poor outcomes.[@R1] At the same time, risk stratification systems should ensure reliable identification of patients who may not need urgent care. Risk scores such as the pneumonia severity index for patients presenting with pneumonia[@R3] or the Global Registry of Acute Coronary Events risk score for patients with myocardial infarction are applicable mainly to specific patient populations.[@R4]

Emerging data suggest that in unselected medical patients presenting to the ED, early warning scores (EWS) (ie, track-and-trigger systems) are gaining importance for risk stratification and that their usage for this purpose may exceed that of classical triage tools such as the Manchester Triage System.[@R5] Of the numerous EWS that have been investigated for this purpose, the National Early Warning Score (NEWS) may be the best evaluated and most widely used.[@R6] It was originally developed in the UK by the Royal College of Physicians to standardise and improve detection of patients at risk for deterioration, with the routine recording of a minimum of physiological parameters.[@R7] Multiple studies have revealed its superiority over other risk stratification tools with regard to prediction of mortality.[@R6] Since its introduction in 2012, NEWS has been validated and widely implemented in different patient populations[@R5] worldwide.[@R5] It has also been used recently for early risk stratification in unselected ED patients and has shown promise in the prediction of mortality.[@R6] The Royal College of Physicians now recommends its use in EDs in its updated NEWS 2 report issued in 2017.[@R7] However, risk stratification at this early stage in patient care immediately following presentation to the ED is challenging due to lack of clinical information. Moreover, NEWS and other triage scores are based on vital signs and represent a patient's clinical state at a single time point when vital signs are frequently still unremarkable, as a consequence of which they may miss patients at risk.

The use of blood markers assessed at the time of ED presentation may add prognostic information[@R17] and even improve the prognostic value of EWSs. Although investigations trying to improve the discriminative value of NEWS by combining different markers such as serum lactate[@R16] or D-dimer[@R19] with NEWS have been undertaken, their results are contradictory. This may be due to inadequate selection of blood markers. The inflammatory blood marker procalcitonin (PCT) is a marker for bacterial infections. It has been employed for stewardship of antibiotic therapy[@R20] and has been shown to improve risk assessment in different patient populations such as those with sepsis[@R21] or malignant disease,[@R22] and in patients at cardiovascular risk.[@R23] Adrenomedullin (ADM) is a potent vasodilator peptide hormone widely expressed by many tissues that acts both as an autocrine and paracrine mediator.[@R24] It is released in higher quantities in infectious and inflammatory states.[@R26] Midregional proadrenomedullin (MR-proADM) is generated during the processing of the prohormone of ADM, is stable in human plasma and may directly reflect the release of ADM.[@R28] Several studies have revealed MR-proADM to be highly predictive of adverse outcomes in specific patient populations such as those with chronic heart failure,[@R29] sepsis,[@R25] lower respiratory tract infections,[@R30] myocardial infarction[@R32] and urinary tract infections.[@R33] Moreover, MR-proADM has been shown to predict adverse outcomes in patients presenting to the ED with non-specific complaints.[@R34]

The first aim of this study was to investigate the prognostic accuracy of NEWS in an unselected multinational cohort of medical patients presenting to the ED. In a second step, we aimed to investigate whether adding the inflammatory blood markers white cell count (WCC), PCT and MR-proADM would improve the predictive value of NEWS at the time of ED presentation.

Methods {#s2}
=======

Study design {#s2a}
------------

This is a retrospective analysis of data from a multinational, observational cohort study that enrolled patients from March 2013 to October 2014 at three tertiary care hospitals in Aarau (Switzerland), Paris (France) and Clearwater (Florida, USA) with the aim of determining whether the addition of biomarkers from distinct biological pathways would improve early risk stratification and initial triage of patients on ED admission. The study protocol and details regarding the study design have been published previously.[@R35]

Patient and public involvement {#s2b}
------------------------------

Patients were not involved in the development of the research question or the design of the study.

Patient samples {#s2c}
---------------

All adult medical patients seeking ED care at one of the participating hospitals were consecutively enrolled. They were included in this analysis if an initial blood draw had been performed as part of the routine assessment in the ED. Surgical and paediatric patients were excluded. There were no further exclusion criteria so as to reflect patient diversity and challenges of 'real-life'.

Data collection and score assignment {#s2d}
------------------------------------

At time of admission to the ED, all patients were assessed by a triage nurse and assigned an initial triage priority based on the routine hospital algorithm. All participants provided a thorough medical history and underwent a physical examination, including measurement of vital signs and laboratory assessment with collection of leftover blood samples for later analysis. Additionally, we recorded the main presenting clinical symptoms and complaints, sociodemographic characteristics and comorbidities. All information was initially entered in a case report form and subsequently stored in a centralised, password-secured databank (SecuTrial; interActive Systems GmbH, Berlin, Germany).

Throughout the hospital stay, the patients were managed by physicians, nurses and social workers independent of the research team. All patients were contacted by telephone interview 30 days after admission using a predefined questionnaire to assess vital and functional status, unplanned hospital readmission and other clinical outcomes.

The NEWS was calculated retrospectively based on available admission data pertaining to the following six parameters: respiratory rate, oxygen saturation, temperature, blood pressure, pulse rate and level of consciousness. Corresponding to the NEWS 2 score chart of the Royal College of Physicians of the UK,[@R7] continuous variables were awarded a range of 0--3 points, while the level of consciousness was binary coded with 0 points if absent and 3 points if altered. Since data on whether supplemental oxygen was given were not available, the additional 2 points that would have been assigned if supplemental oxygen was given were not included in the calculation. Using the resulting aggregate score, patients were classified into three NEWS categories representing low (0--4 points), moderate (5--6 points), or high (≥7 points) risk. Additionally, patients in the low-risk group scoring 3 points for a single physiological parameter were reclassified in the moderate risk group, as recommended by the Royal College of Physicians.[@R7] As data on supplemental oxygen was not available, results in this paper correspond to a NEWS---potentially minus 2 points.

Study endpoints, overall hypothesis and research aim {#s2e}
----------------------------------------------------

The primary endpoint of this analysis was all-cause mortality within 30 days of ED admission. The secondary endpoint was admission to the intensive care unit (ICU) during hospital stay. The decision regarding ICU admission was left to the discretion of the treating physicians. To assess the endpoints, patients were followed throughout their hospital stay, and phone interviews were conducted 30 days after admission. If the patient could not be reached, the patient's family or general practitioner was contacted. The aim of this secondary analysis was to investigate the association of a single calculation of NEWS at time of admission with the respective outcomes. In a second step, we aimed to assess whether the predictive value of NEWS could be improved by combining these prognostic biomarkers with the NEWS.

Blood draws and biomarkers {#s2f}
--------------------------

We decided to investigate associations of three inflammatory biomarkers namely WCC, MR-proADM and PCT. The WCC was part of the routine laboratory measurement at ED admission. Based on the normal range of WCC (4.0--10.0 g/L), we defined the following cut-offs: \<4.0 g/L: representing levels lower than normal, 4.0--10.0 g/L: representing the normal range, 10.01--15.0 g/L: representing low-to-moderate inflammatory response and \>15.0 G/L: representing marked inflammation. Both PCT and MR-proADM were batch-measured later from leftover blood samples. The samples were routinely collected at admission, immediately centrifuged, aliquoted and frozen at −20°C. The results of these analyses were not available at time of hospitalisation. Thus, physicians and patients were blinded to their results. The PCT levels were measured with a highly sensitive time-resolved amplified cryptate emission technology assay (PCT Kryptor, B.R.A.H.M.S. AG, Hennigsdorf, Germany) with a lower detection limit of 0.02 µg/L and assay sensitivity of 0.06 µg/L.[@R37] The MR-proADM levels were measured in plasma with a sandwich immunoassay as described elsewhere.[@R28] The assay has an analytical detection limit of 0.08 nmol/L. We defined cut-offs of PCT and MR-proADM corresponding to quartiles.

Statistical analyses {#s2g}
--------------------

For statistical analyses, we used STATA V.12.1. Two-tailed tests were used, and p values of \<0.05 were considered significant. We used descriptive statistics such as median with quartiles, and frequencies to describe the population, as appropriate. To assess group differences, we used Kruskal-Wallis test for continuous, skew variables, and Pearson's χ^2^ test for categorial and binary variables. We performed logistic regression analyses to investigate associations of NEWS and biomarkers with primary and secondary outcomes, respectively. We developed different models with stepwise adjustment for potential important confounders (ie, age, gender, main diagnoses leading to ED admission and comorbidities). Age was used as a linear covariate. According to the main admission diagnosis, the following diagnostic groups were generated: infectious disease, cardiovascular disease, metabolic disorder, malignant disease, neurological disease, gastrointestinal disease, pulmonary disease and other disease. Comorbidities were assigned using patients' medical history and International Statistical Classification of Diseases and Related Health Problems (ICD-10) diagnostic codes and include chronic obstructive lung disease, heart failure, coronary heart disease, diabetes, hypertension, stroke, malignant disease and renal failure. In statistical models, comorbidities were coded as binary variables. Results of the regression analyses are presented as ORs with 95% CIs. The raw distribution of the biomarker data was skewed. After log transformation with a base of 10, the distribution of the biomarker data approximated a normal distribution. Therefore, ORs correspond to a 10-fold increase in log-transformed values. Regression analyses were repeated in predefined subgroups stratified by diagnoses leading to ED admission. Discriminative performance was determined by means of area under the receiver operating characteristics (AUC), where AUC 0.6--0.7 is considered poor, 0.7--0.8 fair, 0.8--0.9 good, and \>0.9 excellent. The AUCs were systematically calculated for univariate models including NEWS and/or inflammatory markers and not for models adjusted for the aforementioned confounders. We used Pearson's χ^2^ test to compare AUCs. For further illustration, we generated Kaplan-Meier survival plots by NEWS category and for each of the three biomarkers stratified by quartiles.

Results {#s3}
=======

Patient population {#s3a}
------------------

Of a total of 7132 patients presenting to the EDs of the participating hospitals (1000 Clearwater, 1553 Paris and 4579 Aarau), 1303 (940 Clearwater, 355 Paris and 8 Aarau) patients had complete information for calculation of NEWS (excluding data on supplemental oxygen) and were included in the final analysis. A comparison of the total cohort and the cohort selected for this analysis can be found in the online [supplementary materials table A1](#SP1){ref-type="supplementary-material"}. The median age of included patients was 66 years and 50.5% were male. The most frequent main complaints were respiratory symptoms (27.3%), thoracic pain (18.4%) and non-thoracic pain (9.5%). The most prevalent diagnoses at ED admission were cardiovascular disease (37.3%), infections (14.6%), neurological disease (13.5%) and gastrointestinal disease (12.3%). Patients had a high burden of comorbidities including hypertension (43.6%), diabetes (20.6%), coronary heart disease (12.6%) and congestive heart failure (11.8%). Additional baseline characteristics of the general population and stratified by NEWS categories are listed in [table 1](#T1){ref-type="table"}.

10.1136/bmjopen-2018-024636.supp1

###### 

Baseline characteristics in the total cohort and stratified by admission NEWS category

                                                 Total cohort         NEWS category                                                 
  ---------------------------------------------- -------------------- ------------------- -------------------- -------------------- ---------
  Number of patients, n (%)                      1303                 966 (74.1)          262 (20.1)           75 (5.8)             
  Sociodemographics                                                                                                                 
   Age, median (quartiles)                       66 (52, 80)          63 (50, 79)         72 (58, 84)          69 (58, 81)          \<0.001
   Male gender, n (%)                            658 (50.5)           498 (51.6)          122 (46.6)           38 (50.7)            0.36
  Vital signs, median (quartiles)                                                                                                   
   Blood pressure diastolic (mm Hg)              78 (67, 89)          79 (69, 89)         76 (65, 90)          72 (60, 88)          0.015
   Blood pressure systolic (mm Hg)               139 (121, 159)       140 (124, 159)      137 (117, 160)       126 (91, 151)        \<0.001
   Confusion, n (%)                              44 (3.4)             0 (0.0)             32 (12.2)            12 (16.0)            \<0.001
   Pulse (bpm)                                   83 (71, 98)          81 (70, 94)         88 (71, 107)         110 (95, 123)        \<0.001
   Respiratory rate (per min)                    18 (18, 20)          18 (17, 20)         20 (18, 28)          26 (22, 30)          \<0.001
   SpO~2~ (%)                                    97 (95, 99)          98 (96, 99)         96 (93, 98)          91 (88, 95)          \<0.001
   Temperature (°C)                              36.6 (36.2, 36.9)    36.6 (36.2, 36.9)   36.6 (36.2, 37.0)    36.7 (36.0, 37.7)    0.003
  Initial blood biomarkers, median (quartiles)                                                                                      
   Creatinine (µmol/L)                           79.6 (70.7, 106.1)   79.6 (70.7, 97.2)   79.6 (68.0, 107.0)   88.4 (68.0, 140.0)   0.068
   Glucose (mmol/L)                              6.3 (5.3, 8.1)       6.2 (5.2, 7.7)      6.5 (5.3, 8.3)       8.2 (5.8, 12.7)      \<0.001
   White blood cells (g/L)                       8.2 (6.3, 10.8)      7.9 (6.1, 10.4)     9.0 (6.8, 13.0)      10.9 (7.5, 15.6)     \<0.001
   PCT (µg/L)                                    0.08 (0.06, 0.14)    0.08 (0.06, 0.13)   0.09 (0.06, 0.17)    0.12 (0.07, 0.31)    \<0.001
   MR-proADM (nmol/L)                            0.9 (0.6, 1.5)       0.8 (0.6, 1.3)      1.2 (0.7, 1.8)       1.6 (1.1, 2.8)       \<0.001
  Main symptom at ED admission, n (%)                                                                          \<0.001              
   Diarrhoea, vomitus, dysuria                   106 (8.1)            90 (9.3)            12 (4.6)             4 (5.3)              
   Fever                                         23 (1.8)             14 (1.4)            8 (3.1)              1 (1.3)              
   Gastrointestinal bleeding                     31 (2.4)             27 (2.8)            4 (1.5)              0 (0.0)              
   Neurological symptoms                         90 (6.9)             71 (7.3)            17 (6.5)             2 (2.7)              
   Non-thoracic pain                             124 (9.5)            112 (11.6)          11 (4.2)             1 (1.3)              
   Respiratory symptoms                          356 (27.3)           211 (21.8)          103 (39.3)           42 (56.0)            
   Thoracic pain                                 240 (18.4)           212 (21.9)          25 (9.5)             3 (4.0)              
   Miscellaneous                                 333 (25.6)           229 (23.7)          82 (31.3)            22 (29.3)            
  Main diagnosis, n (%)                                                                                        \<0.001              
   Cancer                                        52 (4.0)             44 (4.6)            6 (2.3)              2 (2.7)              
   Cardiovascular                                486 (37.3)           386 (40.0)          83 (31.7)            17 (22.7)            
   Gastrointestinal                              160 (12.3)           137 (14.2)          17 (6.5)             6 (8.0)              
   Infection                                     190 (14.6)           102 (10.6)          57 (21.8)            31 (41.3)            
   Metabolic                                     49 (3.8)             33 (3.4)            15 (5.7)             1 (1.3)              
   Neurological                                  176 (13.5)           140 (14.5)          33 (12.6)            3 (4.0)              
   Pulmonary                                     110 (8.4)            60 (6.2)            37 (14.1)            13 (17.3)            
   Miscellaneous                                 80 (6.1)             64 (6.6)            14 (5.3)             2 (2.7)              
  Comorbidities, n (%)                                                                                                              
   Cancer                                        123 (9.4)            73 (7.6)            37 (14.1)            13 (17.3)            \<0.001
   Chronic renal disease                         96 (7.4)             55 (5.7)            26 (9.9)             15 (20.0)            \<0.001
   Congestive heart failure                      154 (11.8)           88 (9.1)            46 (17.6)            20 (26.7)            \<0.001
   COPD                                          94 (7.2)             46 (4.8)            36 (13.7)            12 (16.0)            \<0.001
   Coronary heart disease                        164 (12.6)           110 (11.4)          43 (16.4)            11 (14.7)            0.080
   Diabetes                                      269 (20.6)           187 (19.4)          64 (24.4)            18 (24.0)            0.15
   History of stroke                             22 (1.7)             12 (1.2)            7 (2.7)              3 (4.0)              0.078
   Hypertension                                  568 (43.6)           432 (44.7)          108 (41.2)           28 (37.3)            0.32

NEWS was calculated without oxygen supplementation data and thus represents 'NEWS - potentially minus 2'.

To assess group differences, we used Kruskal-Wallis test for continuous, skew variables and Pearson's χ^2^ test for categorical and binary variables.

COPD, chronic obstructive pulmonary disease; ED, emergency department; MR-proADM, midregional proadrenomedullin; NEWS, National Early Warning Score; PCT, procalcitonin; SpO~2~, peripheral oxygen saturation (%).

NEWS and mortality {#s3b}
------------------

The 30-day mortality rate following admission to the ED was 4.1%. In unadjusted logistic regression analyses, we found a significant association between 30-day mortality and NEWS overall (OR 1.35, 95% CI 1.23 to 1.48, p\<0.001) and stratified into risk groups with corresponding ORs of 2.45 (95% CI 1.29 to 4.66, p=0.006) for the moderate risk NEWS category and 7.89 (95% CI 3.85 to 16.18, p\<0.001) for the high risk NEWS category, respectively, compared with the low risk NEWS category. These associations remained robust after stepwise adjustment for confounders (see [table 2](#T2){ref-type="table"} for univariate and fully adjusted ORs. Data on all of the remaining models are presented in the online [supplementary materials table A2](#SP1){ref-type="supplementary-material"}). Receiver operating statistics showed fair discriminative performance with regard to 30-day all-cause mortality, with an AUC of 0.73 (95% CI 0.66 to 0.80).

###### 

Regression analyses for associations of NEWS and blood markers with primary and secondary outcomes

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
                  30-day mortality   ICU admission                                                                                    
  --------------- ------------------ -------------------------- -------------------------- ----------------- ------------------------ ------------------------
  Total cohort    54/1303 (4.1)                                                            171/1303 (13.1)                            

  NEWS                                                                                                                                

   Low            25/966 (2.6)       Ref.                       Ref.                       89/966 (9.2)      Ref.                     Ref.

   Moderate       16/262 (6.1)       2.45 (1.29 to 4.66),\      1.71 (0.87 to 3.37),\      57/262 (21.8)     2.74 (1.90 to 3.95),\    2.71 (1.85 to 3.98),\
                                     p=0.006                    p=0.123                                      p\<0.001                 p\<0.001

   High           13/75 (17.3)       7.89 (3.85 to 16.18),\     4.89 (2.22 to 10.75),\     25/75 (33.3)      4.93 (2.91 to 8.35),\    4.33 (2.48 to 7.57),\
                                     p\<0.001                   p\<0.001                                     p\<0.001                 p\<0.001

   Continuous                        1.35 (1.23 to 1.48),\      1.26 (1.13 to 1.40),\                        1.25 (1.17 to 1.33),\    1.24 (1.15 to 1.32),\
                                     p\<0.001                   p\<0.001                                     p\<0.001                 p\<0.001

  WCC (g/L)                                                                                                                           

   4.0--10.0      27/829 (3.3)       Ref.                       Ref.                       84/829 (10.1)     Ref.                     Ref.

   10.01--15.0    10/299 (3.3)       1.03 (0.49 to 2.15),\      1.07 (0.50 to 2.31),\      41/299 (13.7)     1.41 (0.95 to 2.10),\    1.52 (1.01 to 2.29),\
                                     p=0.942                    p=0.855                                      p=0.092                  p=0.045

   \>15.0         15/111 (13.5)      4.64 (2.39 to 9.03),\      3.73 (1.80 to 7.75),\      27/111 (24.3)     2.85 (1.75 to 4.65),\    2.78 (1.67 to 4.62),\
                                     p\<0.001                   p\<0.001                                     p\<0.001                 p\<0.001

   \<4.0          2/46 (4.4)         1.35 (0.31 to 5.86),\      1.05 (0.22 to 4.99),\      15/46 (32.6)      4.29 (2.23 to 8.27),\    4.42 (2.21 to 8.84),\
                                     p=0.689                    p=0.951                                      p\<0.001                 p\<0.001

   Continuous                        1.02 (1.00 to 1.03),\      1.02 (1.00 to 1.03),\                        1.01 (0.99 to 1.02),\    1.01 (0.99 to 1.02),\
                                     p=0.051                    p=0.036                                      p=0.355                  p=0.267

  PCT                                                                                                                                 

   1st quartile   5/321 (1.6)        Ref.                       Ref.                       27/321 (8.4)      Ref.                     Ref.

   2nd quartile   7/321 (2.2)        1.41 (0.44 to 4.49),\      1.24 (0.38 to 4.09),\      34/321 (10.6)     1.29 (0.76 to 2.19),\    1.23 (0.72 to 2.11),\
                                     p=0.562                    p=0.722                                      p=0.347                  p=0.449

   3rd quartile   10/321 (3.1)       2.03 (0.69 to 6.01),\      1.79 (0.59 to 5.45),\      36/321 (11.2)     1.38 (0.81 to 2.32),\    1.35 (0.79 to 2.29),\
                                     p=0.200                    p=0.306                                      p=0.234                  p=0.276

   4th quartile   32/322 (9.9)       6.97 (2.68 to 18.14),\     5.17 (1.88 to 14.18),\     73/322 (22.7)     3.19 (1.99 to 5.12),\    2.78 (1.68 to 4.59),\
                                     p\<0.001                   p=0.001                                      p\<0.001                 p\<0.001

   Continuous                        2.66 (1.81 to 3.92),\      2.45 (1.54 to 3.89),\                        2.33 (1.76 to 3.08),\    2.18 (1.61 to 2.96),\
                                     p\<0.001                   p\<0.001                                     p\<0.001                 p\<0.001

  MR-proADM                                                                                                                           

   1st quartile   1/324 (0.3)        Ref.                       Ref.                       20/324 (6.2)      Ref.                     Ref.

   2nd quartile   6/325 (1.9)        6.08 (0.73 to 50.75),\     4.93 (0.57 to 42.58),\     36/325 (11.1)     1.89 (1.07 to 3.35),\    2.26 (1.24 to 4.13),\
                                     p=0.096                    p=0.147                                      p=0.028                  p=0.008

   3rd quartile   12/323 (3.7)       12.46 (1.61 to 96.42),\    7.93 (0.96 to 65.37),\     34/323 (10.5)     1.79 (1.01 to 3.18),\    2.25 (1.19 to 4.27),\
                                     p=0.016                    p=0.054                                      p=0.048                  p=0.013

   4th quartile   35/326 (10.7)      38.85 (5.29 to 285.36),\   17.18 (2.15 to 137.36),\   81/326 (24.9)     5.03 (3.00 to 8.43),\    6.27 (3.36 to 11.68),\
                                     p\<0.001                   p=0.007                                      p\<0.001                 p\<0.001

   Continuous                        17.58 (8.05 to 38.38),\    10.33 (3.77 to 28.34),\                      7.65 (4.59 to 12.75),\   9.20 (4.83 to 17.51),\
                                     p\<0.001                   p\<0.001                                     p\<0.001                 p\<0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

Fully adjusted model adjusted for age, sex, main diagnosis and comorbidities.

For regression analysis with continues values, PCT and proADM were log transformed with a base of 10 before entering into statistical models. Therefore, the ORs correspond to a 10-fold increase in PCT and MR-proADM values.

NEWS was calculated without oxygen supplementation data and thus represents 'NEWS - potentially minus 2'.

ICU, intensive care unit; MR-proADM, midregional proadrenomedullin; NEWS, National Early Warning Score; PCT, procalcitonin; WCC, white cell count.

Incremental impact of inflammatory blood markers on prediction of mortality {#s3c}
---------------------------------------------------------------------------

The inflammatory blood markers WCC, PCT and MR-proADM showed low to fair prognostic accuracy for prediction of 30 day mortality with AUCs of 0.64 (95% CI 0.56 to 0.72), 0.71 (95% CI 0.64 to 0.79) and 0.78 (95% CI 0.73 to 0.84), respectively. Corresponding regression analyses for continuous values and stratified by cut-offs are shown in [table 2](#T2){ref-type="table"}. Adding all three markers to NEWS significantly improved the predictive value to an AUC of 0.82 (95% CI 0.77 to 0.88, p=0.002). Interestingly, adding only MR-proADM to a model with NEWS showed a similar AUC of 0.82 (95% CI 0.77 to 0.87, p=0.002) for prediction of mortality ([table 3](#T3){ref-type="table"}, [figure 1](#F1){ref-type="fig"}). We further calculated Kaplan-Meier survival estimates ([figure 2](#F2){ref-type="fig"}).

###### 

Discriminative performance of NEWS and biomarkers for the prediction of primary and secondary outcomes

                    AUROC (95% CI)                                      
  ----------------- --------------------- ------- --------------------- -------
  NEWS              0.73 (0.66 to 0.80)           0.65 (0.61 to 0.70)   
  WCC               0.64 (0.56 to 0.72)           0.54 (0.49 to 0.59)   
  PCT               0.71 (0.64 to 0.79)           0.62 (0.57 to 0.67)   
  ProADM            0.78 (0.73 to 0.84)           0.67 (0.62 to 0.72)   
  All combined      0.82 (0.77 to 0.88)   0.002   0.70 (0.65 to 0.75)   0.006
  NEWS and WCC      0.74 (0.67 to 0.81)   0.196   0.65 (0.60 to 0.70)   0.792
  NEWS and PCT      0.78 (0.72 to 0.84)   0.004   0.68 (0.64 to 0.73)   0.017
  NEWS and proADM   0.82 (0.77 to 0.87)   0.002   0.70 (0.65 to 0.74)   0.009

NEWS was calculated without oxygen supplementation data and thus represents 'NEWS - potentially minus 2'.

P values correspond to the AUROCs of the respective models compared with the AUROC of NEWS alone and were assessed using Pearson's χ^2^ test.

AUROC, area under the receiver operating curve; ICU, intensive care unit; MR-proADM, midregional proadrenomedullin; NEWS, National Early Warning Score; PCT, procalcitonin; WCC, white cell count.

![Discriminative performance of NEWS, blood markers and combination of NEWS and blood markers for the prediction of all-cause 30-day mortality (A) and ICU admission (B). NEWS was calculated without oxygen supplementation data and thus represents 'NEWS - potentially minus 2'. NEWS, National Early Warning Score; MR-proADM, midregional proadrenomedullin; PCT, procalcitonin; WCC, white cell count.](bmjopen-2018-024636f01){#F1}

![Kaplan-Meier survival estimates stratified by admission NEWS category (A), white cell count (WCC) (B), procalcitonin (PCT) (C), and MR-proadrenomedullin (MR-proADM) (D). NEWS was calculated without oxygen supplementation data and thus represents 'NEWS - potentially minus 2'.](bmjopen-2018-024636f02){#F2}

NEWS and ICU admission {#s3d}
----------------------

During their hospital stay, 13.1% of patients were admitted to the ICU. Similar to findings with the primary endpoint, unadjusted regression analyses showed significant associations of NEWS with ICU admission (OR 1.25, 95% CI 1.17 to 1.33, p\<0.001). Stratification of NEWS by risk categories showed respective ORs of 2.74 (95% CI 1.90 to 3.95, p\<0.001) for the moderate risk category and 4.93 (95% CI 2.91 to 8.35, p\<0.001) for the high risk category, compared with the low risk category. As before, the results stayed robust after adjusting for important confounders (see [table 2](#T2){ref-type="table"} for univariate and fully adjusted ORs. All of the remaining models are presented in the online [supplementary materials table A3](#SP1){ref-type="supplementary-material"}).

When receiver operating statistics were determined, NEWS showed low discriminative performance with regard to ICU admission (AUC 0.65, 95% CI 0.61 to 0.70).

Incremental impact of inflammatory blood markers on prediction of ICU admission {#s3e}
-------------------------------------------------------------------------------

The predictive value of the blood markers WCC (AUC 0.54, 95% CI 0.49 to 0.59), PCT (AUC 0.62, 95% CI 0.57 to 0.67) and MR-proADM (AUC 0.67, 95% CI 0.62 to 0.72) for ICU admission was low, with only MR-proADM showing slightly better prognostic accuracy than NEWS. For univariate and multivariate regression analyses for associations of blood markers with ICU admission, see [table 2](#T2){ref-type="table"}. A combined model of NEWS with all three blood markers again improved discriminative performance (AUC 0.70, 95% CI 0.65 to 0.75, p=0.006). Similar to the association with mortality, a model including only NEWS and MR-proADM showed equal results for prediction of ICU admission (AUC 0.70, 95% CI 0.65 to 0.74, p=0.009) ([table 3](#T3){ref-type="table"}, [figure 1](#F1){ref-type="fig"}).

Subgroup analyses {#s3f}
-----------------

Analyses of subgroups showed similar association of NEWS with 30-day mortality among different diagnoses leading to ED admission (online [supplementary materials figure A1](#SP1){ref-type="supplementary-material"}).

Discussion {#s4}
==========

This multinational study of heterogenous medical ED patients found a fair performance of the NEWS for prediction of 30-day mortality when calculated at a single time point at ED admission. Results remained robust after adjustment for potential confounders and among different subgroups. Additionally, we found that the predictive value of NEWS was improved by adding inflammatory blood markers, in particular MR-proADM. We also found the discriminative value of NEWS for prediction of our secondary outcome, ICU admission, was less strong but was also improved by adding PCT and MR-proADM to the model.

The 30-day mortality in our study (4.1%) was in line with the 4.0%--5.7% reported in other investigations that included similar patient populations and examined similar outcome measures.[@R19] Prevalence of ICU admission during hospital stay in our study (13.1%) was within ICU admission rates in several other studies that reported a range between 1% and 17.4%.[@R5] This wide range may be a reflection of different healthcare systems studied and particularly of different follow-up periods, as the different investigations examined short-term outcomes within 24 or 48 hours of admission, respectively. In this respect, our results are most notably consistent with the findings of several Scandinavian studies.[@R5]

Regarding predictive performance, other studies investigating discriminative power of NEWS documented at the time of ED arrival found similar AUCs for prediction of in-hospital mortality or 30-day mortality, with reported AUCs of 0.65--0.77 in patients with suspected infection/sepsis[@R40] and AUCs of 0.77 to 0.84 in general ED patients, respectively.[@R16]

Predictive performance for ICU admission in our study (AUC 0.65, 95% CI 0.61 to 0.70) was slightly lower than the AUCs in other publications that report AUCs of 0.67--0.857 for prediction of ICU admission in different patient populations.[@R9]

Our finding of MR-proADM as a solitary predictor of 30-day mortality (AUC 0.78, 95% CI 0.73 to 0.84) is in line with the result of another Swiss study reporting an AUC of 0.732 for the same purpose in a cohort of patients with non-specific complaints presenting to the ED.[@R34]

To the best of our knowledge, this is the first study investigating NEWS in a multinational cohort of medical ED patients. Moreover, this is the first study investigating the potential additional impact of promising inflammatory markers, namely PCT and MR-proADM, on NEWS for the prediction of adverse outcome.

One could argue that adding blood markers to a clinical score might complicate its calculation, but in EDs, initial blood draws are part of routine care, which is why the additional determination of inflammatory marker levels do not change existing processes. In contrast, WCC results are available rapidly, and indeed PCT point-of-care tests that provide results within minutes are being developed.[@R44] Measurements of additional blood markers thus might partially overcome user-dependency of EWSs and might therefore improve early risk stratification. Our study reveals that MR-proADM could be a particularly suitable and promising blood marker for early risk stratification when combined with a clinical score such as NEWS. As a result, identification of patients needing urgent care could be improved. However, right now, there is no point-of-care test available that would allow rapid measurement of MR-proADM. Clinicians would likely evaluate results from biomarker assays in the light of the patient's condition at the time the test results become available, not at time the blood sample was drawn. As ED patients are in a dynamic situation, NEWS and the patient's condition might have changed already when results become available.

This study has some limitations. First, since it is a study where NEWS was calculated retrospectively, associations between NEWS and biomarkers and outcomes are likely confounded. We addressed this limitation at least partially by adjusting for important confounders. However, with residual confounding being likely, our results are at best hypothesis generating. Second, NEWS was calculated retrospectively, and vital signs were not measured more frequently than standard clinical practice. However, we addressed possible bias regarding a treatment paradox since observed mortality may be lower in studies where NEWS is acted on. Third, due to missing vital sign data---particularly respiratory rate---a large number of patients were not eligible for final analysis. This is in line with other studies reporting that EWS were often incomplete[@R45] and that among others, respiratory rate was documented in only 30%--60% of cases.[@R45] However, our sample is still relatively large and represents a multinational cohort of unselected medical ED patients. Moreover, given that health system organisation strongly influences populations at EDs, the multinational nature of our study provides external validity. However, there is the possibility of a selection bias as the cohort included in this analysis differed to the initial total cohort in age, some of the main symptoms and main diagnoses at ED admission and comorbidities. This was addressed in the regression models by adjusting for the aforementioned confounders. The results remained robust. Fourth, information on the use of oxygen support was not available retrospectively and therefore did not contribute to NEWS calculation, which reduced the maximum score from 20 to 18. This might have led to misclassification of patients and might have diminished the discriminatory power of NEWS. It is likely that the fraction of patients that were under-rated by 2 points due to missing information on oxygen supplements would increase from the low via the moderate to the high-risk NEWS group. This could represent at systematical bias where sicker patients (probably with worse outcomes) would potentially be misclassified with fewer points in the NEWS score, possibly resulting in statistical inflation of the effect of the lower NEWS values. However, the Royal College of Physicians recommends addition of a weighting score of 2 not by default for all patients with supplemental oxygen but only for patients requiring supplemental oxygen to maintain their optimal oxygen saturation.[@R7] As the optimal oxygen saturation may be different in varying patient groups, most notably in patients with hypercapnic respiratory failure, the actual requirement of supplemental oxygen is hard to determine and requires evaluation of a qualified and experienced physician. As a result, certain patients might mistakenly score 2 additional points for supplemental oxygen, which can again result in misclassification of the NEWS risk category. However, as mentioned before, the discriminative power of NEWS in our study is comparable with other similar investigations. Fifth, we only had a few events that could limit reliability and is reflected in the rather broad 95% CIs. This was addressed at least in part by hard endpoints and a structured follow-up with phone interviews 30 days after admission or through contacting the patient's family or general practitioner. Sixth, the decision regarding ICU admission was left to the discretion of treating physicians. This reflects procedures followed in the included centres and may be different from those in other hospitals. Last, NEWS was not designed to be a single time point tool but rather a 'track-and-trigger' system in individual patients. Accuracy of NEWS may thus be different if multiple measurements at different time points are considered.

Conclusion {#s5}
==========

Combining NEWS calculated on admission to the ED with markers of inflammation such as MR-proADM and PCT improves the predictive value of NEWS in unselected medical patients. The combination of NEWS and MR-proADM might prove to be a particularly promising tool for early risk stratification. Whether these theoretical benefits of improved risk stratification at ED admission can be translated into improved outcomes has to be examined in future interventional studies.
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